Thus, no conclusions about quantitative changes in the numbers of GLP‐1 expressing cells in T2D or obesity can be made, and it is not clear whether the alteration of the numbers of intestinal GLP‐1 producing cells explains the reduced incretin effect in some patients with T2D or obesity. The gene discussed is GCG; the disease is obesity disorder.